{"id":"W2971816470","doi":"10.1111/bjd.18484","title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Merck","keywords":"Dosing; Etanercept; Medicine; Plaque psoriasis; Psoriasis; Pharmacology; Dermatology; Internal medicine; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001145661,0.0002504241,0.001105991,0.0001153587,0.0001462442,0.00002309344,0.0001148114,0.0002229483,0.00004008488],"category_scores_gemma":[0.00007790023,0.0002083238,0.0001090388,0.00004993716,0.0001644951,0.0001565707,0.00004641438,0.0001421193,0.000004561162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005959396,"about_ca_system_score_gemma":0.00006910248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004524747,"about_ca_topic_score_gemma":0.0002440768,"domain_scores_codex":[0.9982743,0.0002424169,0.000853932,0.0003257677,0.00004872398,0.000254816],"domain_scores_gemma":[0.9979986,0.0008439984,0.0007842852,0.0001562658,0.000168634,0.00004820423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.099534,0.002137089,0.01504461,0.00007759706,0.01526538,0.001399579,0.01297251,0.000007783305,0.06054517,0.00005285207,0.001182643,0.7917808],"study_design_scores_gemma":[0.6949766,0.01074773,0.1004058,0.003905992,0.007236696,0.05542431,0.01164384,0.00002660484,0.1012449,0.0005321326,0.01263839,0.001217008],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.963687,0.03411222,0.0001369816,0.0001950611,0.0005623397,0.0004881196,0.0007757439,0.00001320972,0.00002930361],"genre_scores_gemma":[0.9910905,0.007669555,0.0007811476,0.00003998368,0.00005205689,0.00001219889,0.0002502358,0.00001992013,0.00008442828],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7905638,"threshold_uncertainty_score":0.8495198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02410772837681473,"score_gpt":0.2871277570869232,"score_spread":0.2630200287101084,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}